Understand the source comparison
Dihexa FAQ: Mechanism Comparison Table
Dihexa HGF mimetic; activates c-Met receptor signaling c-Met (hepatocyte growth factor receptor) Crosses BBB via lipophilic modification 10,000,000× (femtomolar active concentrations) Unmatched synaptogenic potency but limited long-term stability data; require
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Dihexa
- HGF mimetic; activates c-Met receptor signaling
- c-Met (hepatocyte growth factor receptor)
- Crosses BBB via lipophilic modification
- 10,000,000× (femtomolar active concentrations)
- Unmatched synaptogenic potency but limited long-term stability data; requires precise concentration control
- BDNF
- Direct neurotrophic factor; binds TrkB receptors
- TrkB (tropomyosin receptor kinase B)
- Poor BBB penetration; requires direct CNS administration
- 1× (reference standard)
- Gold standard for neurotrophic research but impractical for systemic or oral studies
- Cerebrolysin
- Peptide mixture; neurotrophic and neuroprotective effects
- Multiple; BDNF, NGF, CNTF activity
- Active peptides cross BBB
- 10–100× estimated
- Established clinical use and safety profile; less specific mechanism than pure compounds
- Semax
- ACTH(4-10) analogue; modulates BDNF expression
- Indirect via melanocortin receptors
- Crosses BBB; intranasal administration effective
- 100–1,000× estimated
- Well-characterized stability; multiple administration routes; lower potency requires higher doses
- P21
- CREB activation; downstream BDNF upregulation
- Indirect via CREB pathway
- Requires CNS administration for optimal effect
- 1,000–10,000× estimated
- Emerging research compound; mechanism targets transcriptional regulation rather than direct receptor binding
- This comparison reveals why dihexa FAQ discussions consistently emphasize concentration precision. The potency differential means effective doses measured in micrograms rather than milligrams common to other nootropic peptides.